TG Therapeutics, Inc.TGTX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · tgtherapeutics.com
Commercial-stage biopharmaceutical company focused on B-cell diseases; markets Briumvi (ublituximab) for relapsing forms of multiple sclerosis.
Key ratios
EPS growth
667.5%TTM
2025
1746.7%2024
68.0%
FCF / Sales
-4.1%2025
2024
-12.3%2023
-13.4%
Net margin
55.2%TTM
2025
72.6%2024
7.1%2023
5.4%
ROA
7.3%TTM
2025
9.4%2024
5.8%2023
4.9%
ROE
100.3%TTM
2025
102.8%2024
12.2%2023
11.6%
Revenue growth
87.3%2025
2024
40.8%2023
8290.0%
Track TGTX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer